|
The state-of-the-art upstream processing areas and technologies
have been designed to provide maximum flexibility and capacity
to meet the needs of clients requiring process development
from early development stages through to the provision of
product for use in all phases of clinical trials.
Alpha
has the capability, through the production technologies and
facility design, to perform a number of the stages in parallel
whilst still ensuring cGMP compliance with the goal of moving
through each stage of the process development and manufacturing
cycle as quickly and efficiently as possible. The combined
effects enable Alpha to deliver product to our clients earlier
than expected, thereby significantly reducing the cost of
their drug development programmes.
|
